Board of Directors

Niclas Lundqvist Chairman of the Board

Born in 1965.
Chairman of the Board since September 2020.

Education and experience:
Niclas Lundqvist (born in 1965) holds a degree of master of laws and has previously served at the Swedish National Courts Administration. He has also practiced law as a business lawyer specializing in contract law and corporate finance. Entrepreneur who has established a number of businesses, for example, a Swedish securities company with authorization from the Swedish Financial Supervisory Authority. Solid experience as board member in listed companies (including Cantargia AB and Rhovac AB) and companies under the supervision of the Swedish Financial Supervisory Authority. Extensive experience also of financial consultancy and legal consultancy in the fields of corporate, stock-exchange and securities law for listed and soon-to-be-listed companies.

Shareholding:
Niclas Lundqvist does not own any shares in Coegin Pharma AB, neither privately nor through companies.

Tore Duvold Member of the Board and CEO

Born in 1968.
Member of the board and Chief Executive Officer since September 2020.

Education and experience:
Tore Duvold has more than 20 years' experience in the pharmaceutical and biotechnology industries, with extensive experience in dermatological diseases, antibiotics and kidney diseases. Tore Duvold was the CEO of Aker Biopharma AS and Senior Vice President and part of the Group management of LEO Pharma. His most recent position was at Innovation Fund Denmark, where he took up position as Vice President and was later appointed Chief Executive Officer. Tore Duvold has held directorships and served in advisory boards at both Technical University of Denmark and University of Copenhagen. Tore Duvold holds a degree in organic chemistry from the University of Bergen and a ph.d dsegree from Université Louis Pasteur in France.

Shareholding:
Tore Duvold owns 1,000,000 warrants i Coegin Pharma AB.

Jesper Kihl Member of the board

Born in 1958.
Member of the board since September 2020. 

Education and experience:
Jesper Kihl (born in 1958) holds a Master of Science in Chemical Engineering from Technical University of Denmark and has more than 40 years' experience within life science and medtech, mostly from leading positions. He spent 14 years at LEO Pharma A/S, in positions such as Vice President Global Regulatory Affairs. Prior to that, he served at Novo Nordisk for 22 years, active in manufacturing, quality, development, marketing and logistics. Jesper Kihl is and has been a member of several Advisory Boards, including for Biogenity, and works with funds, universities and other institutions.

Shareholding:
Jesper Kihl does not own any shares in Coegin Pharma AB, neither privately nor through companies.

Lars Persson Member of the board

Born in 1955.
Member of the board since September 2020. 

Education and experience:
Lars Persson (born in 1955), M.Sc. in chemistry, has more than 25 years of experience from senior positions in medtech and venture capital. His previous positions include Atos Medical AB, Stiftelsen Industrifonden, and, most recently, CEO of Almi Invest Syd AB. He further has experience as Chairman and board member in several companies, including Invent Medic Sweden AB.

Shareholding:
Lars Persson privately owns 385,000 shares in Coegin Pharma AB, and an additional 3,249,400 shares through Mandelträdet AB, in which he owns 50 percent of the shares.

Erlend Skagseth Member of the board

Born in 1955.
Member of the board since September 2020.

Education and experience:
Erlend Skagseth (born in 1955) holds an MBA and has 30 years' experience in R&D-based project management and business development, and more than 15 years' experience in VC investments. Erlend Skagseth is Managing Partner at Sarsia Seed and has taken part in several turnarounds and negotiated a number of international contracts, licenses and exits. He has extensive experience from board work in development and growth companies.

Shareholding:
Sarisa Seed AS owns 14,483,802 shares in Coegin Pharma AB. Indirectly through companies, Erlend Skagseth owns approximately 5 percent of the shares in Sarisa Seeds AS.